{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:44:57Z","timestamp":1791499497466,"version":"4.3.4"},"reference-count":57,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Moraine Corporation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>QTc prolongation and torsade de pointes (TdP) are significant adverse events linked to azole antifungals. Reports on QTc interval prolongation caused by these agents are limited. In this study, we report a case of a 77-year-old male with cardiovascular disease who experienced QTc prolongation and subsequent TdP while being treated with fluconazole for Candida albicans-induced knee arthritis. Additionally, a literature review was conducted on cases where QTc prolongation and TdP were triggered as adverse events of azole antifungal drugs. The case study detailed the patient\u2019s experience, whereas the literature review analyzed cases from May 1997 to February 2023, focusing on patient demographics, underlying diseases, antifungal regimens, concurrent medications, QTc changes, and outcomes. The review identified 16 cases, mainly in younger individuals (median age of 29) and women (75%). Fluconazole (63%) and voriconazole (37%) were the most common agents. Concurrent medications were present in 75% of cases, and TdP occurred in 81%. Management typically involved discontinuing or switching antifungals and correcting electrolytes, with all patients surviving. Risk assessment and concurrent medication review are essential before starting azole therapy. High-risk patients require careful electrocardiogram monitoring to prevent arrhythmias. Remote monitoring may enhance safety for patients with implanted devices. Further studies are needed to understand risk factors and management strategies.<\/jats:p>","DOI":"10.3390\/microorganisms12081619","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:13:14Z","timestamp":1723119194000},"page":"1619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["QTc Interval Prolongation as an Adverse Event of Azole Antifungal Drugs: Case Report and Literature Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-1338","authenticated-orcid":false,"given":"Shiori","family":"Kitaya","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"},{"name":"Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"},{"name":"Laboratory Medicine, Department of Infectious Diseases, Kanazawa University, Kanazawa 920-8641, Ishikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-7542","authenticated-orcid":false,"given":"Makoto","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Katori","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3026-5272","authenticated-orcid":false,"given":"Hajime","family":"Kanamori","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan"},{"name":"Laboratory Medicine, Department of Infectious Diseases, Kanazawa University, Kanazawa 920-8641, Ishikawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"ref_1","unstructured":"Walsh, E.P., Saul, J.P., and Triedman, J.K. (2001). Long QT syndrome. Cardiac Arrhythmias in Children and Young Adults with Congenital Heart Disease, Lippincott Williams & Wilkins."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.12659\/AJCR.896946","article-title":"Long QT syndrome leading to multiple cardiac arrests after posaconazole administration in an immune-compromised patient with sepsis: An unusual case report","volume":"17","author":"Panos","year":"2016","journal-title":"Am. J. Case Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated QT interval prolongation: Pointes of interest","volume":"43","author":"Owens","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8167.2006.00408.x","article-title":"QT interval: How to measure it and what is \u201cnormal\u201d","volume":"17","author":"Goldenberg","year":"2006","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"106518","DOI":"10.1016\/j.ijantimicag.2022.106518","article-title":"Current status and structure activity relationship of privileged azoles as antifungal agents (2016\u20132020)","volume":"59","author":"Ahmadi","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11333","DOI":"10.3390\/molecules190811333","article-title":"Synthesis and antifungal activity of novel triazole compounds containing piperazine moiety","volume":"19","author":"Wang","year":"2014","journal-title":"Molecules"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-019-01127-8","article-title":"Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents","volume":"79","author":"Benitez","year":"2019","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00228-017-2284-5","article-title":"Voriconazole-induced QT prolongation among hemato-oncologic patients: Clinical characteristics and risk factors","volume":"73","author":"Gueta","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1080\/10428194.2019.1639165","article-title":"QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia","volume":"60","author":"Barreto","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/AAC.00958-12","article-title":"Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients","volume":"57","author":"Zeuli","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/apa.14652","article-title":"Voriconazole-induced QTc prolongation in a paediatric population","volume":"108","author":"Pasternak","year":"2019","journal-title":"Acta Paediatr."},{"key":"ref_13","first-page":"228","article-title":"Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone","volume":"74","author":"Mourad","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/bcp.13457","article-title":"QTc prolongation during ciprofloxacin and fluconazole combination therapy: Prevalence and associated risk factors","volume":"84","author":"Berger","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/dmd.30.3.314","article-title":"Inhibition of cytochromes P450 by antifungal imidazole derivatives","volume":"30","author":"Zhang","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1046\/j.1365-2036.1999.00655.x","article-title":"Review article: Cardiac adverse effects of gastrointestinal prokinetics","volume":"13","author":"Tonini","year":"1999","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","first-page":"1244","article-title":"Fluconazole-induced long QT syndrome via impaired human ether-a-go-go-related gene (hERG) protein trafficking in rabbits","volume":"19","author":"Wang","year":"2017","journal-title":"Europace"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-131-10-199911160-00034","article-title":"Long QT syndrome and torsade de pointes in a patient receiving fluconazole","volume":"131","author":"Wassmann","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2125.2000.00163.x","article-title":"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice","volume":"49","author":"Libersa","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejphar.2010.10.010","article-title":"Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking","volume":"650","author":"Han","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0735-6757(00)90027-5","article-title":"Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline","volume":"18","author":"Dorsey","year":"2000","journal-title":"Am. J. Emerg. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/bja\/ael118","article-title":"Acute respiratory distress syndrome with transiently impaired left ventricular function and torsades de pointes arrhythmia unmasking congenital long QT syndrome in a 25-yr-old woman","volume":"97","author":"Hinterseer","year":"2006","journal-title":"Br. J. Anaesth."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1345\/aph.1G741","article-title":"Long QTc interval and torsade de pointes caused by fluconazole","volume":"40","author":"Pham","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2710.2007.00812.x","article-title":"Inherited long QT syndrome revealed by antifungals drug-drug interaction","volume":"32","author":"Eiden","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s00246-007-9076-0","article-title":"Torsades de pointes ventricular tachycardia in a pediatric patient treated with fluconazole","volume":"29","author":"Esch","year":"2008","journal-title":"Pediatr. Cardiol."},{"key":"ref_27","first-page":"105","article-title":"Torsade de pointes during sevoflurane anesthesia and fluconazole infusion in a patient with long QT syndrome. A case report","volume":"62","author":"Tacken","year":"2011","journal-title":"Acta Anaesthesiol. Belg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1442-200X.2010.03321.x","article-title":"Voriconazole-induced QT interval prolongation and torsades de pointes","volume":"53","author":"Aypar","year":"2011","journal-title":"Pediatr. Int."},{"key":"ref_29","first-page":"100","article-title":"OTc prolongation and torsade de pointes ventricular tachycardia in a small dose voriconazole therapy","volume":"16","author":"Elbey","year":"2012","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1111\/tid.12712","article-title":"Use of isavuconazole in a patient with voriconazole-induced QTc prolongation","volume":"19","author":"Trang","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1177\/1078155218815743","article-title":"Concomitant use of levofloxacin and fluconazole leading to possible torsades de pointes","volume":"25","author":"Tilton","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1017\/S1047951121001992","article-title":"Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient","volume":"31","year":"2021","journal-title":"Cardiol. Young"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Wang, C., and Yao, H. (2023). A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.984572"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","article-title":"Development of a risk score for QTc-prolongation: The RISQ-PATH study","volume":"39","author":"Vandael","year":"2017","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_35","unstructured":"Cancer Research, UK (2003, March 13). Cancer Statistics Reports for the UK. Available online: https:\/\/crediblemeds.org\/."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1056\/NEJM199209173271204","article-title":"The spectrum of symptoms and QTc intervals in carriers of the gene for the long-QT syndrome","volume":"327","author":"Vincent","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1001\/jama.1993.03510210076031","article-title":"Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs","volume":"270","author":"Makkar","year":"1993","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2010.01.001","article-title":"Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"55","author":"Drew","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.CIR.93.3.407","article-title":"Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence","volume":"93","author":"Yang","year":"1996","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/bjaceaccp\/mkn003","article-title":"Long QT syndrome","volume":"8","author":"Hunter","year":"2008","journal-title":"Contin. Educ. Anaesth. Crit. Care Pain."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.18433\/jpps32867","article-title":"Torsade de pointes\/QT prolongation associated with antifungal triazoles: A pharmacovigilance study based on the U.S. FDA Adverse Event Reporting System (FAERS)","volume":"25","author":"Yu","year":"2022","journal-title":"J. Pharm. Pharm. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: Drug-induced QT prolongation and torsades de pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1111\/j.1540-8159.2007.00595.x","article-title":"Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems: Analysis of a worldwide database","volume":"30","author":"Lazarus","year":"2007","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.33963\/KP.a2021.0112","article-title":"Effect of a mobile application and smart devices on heart rate variability in diabetic patients with high cardiovascular risk: A sub-study of the LIGHT randomized clinical trial","volume":"79","author":"Pay","year":"2021","journal-title":"Kardiol. Pol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e753","DOI":"10.1016\/j.ijid.2011.06.004","article-title":"Voriconazole-related severe adverse events: Clinical application of therapeutic drug monitoring in Korean patients","volume":"15","author":"Kim","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"ref_46","first-page":"149","article-title":"Clinical hepatotoxicity associated with antifungal agents","volume":"16","author":"Kyriakidis","year":"2017","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2217\/pgs.11.18","article-title":"Pharmacogenomics of the triazole antifungal agent voriconazole","volume":"12","author":"Mikus","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/myc.13565","article-title":"Does metabolite matter? Defining target itraconazole and hydroxy-itraconazole serum concentrations for blastomycosis","volume":"66","author":"Firkus","year":"2023","journal-title":"Mycoses"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: A meta-analysis","volume":"71","author":"Luong","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/588300","article-title":"Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America","volume":"46","author":"Chapman","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: A pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.2147\/IJN.S93105","article-title":"Fungal diseases: Could nanostructured drug delivery systems be a novel paradigm for therapy?","volume":"11","author":"Voltan","year":"2016","journal-title":"Int. J. Nanomed."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/8\/1619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:32:16Z","timestamp":1760110336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/8\/1619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["microorganisms12081619"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms12081619","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]}}}